Intravenous Lidocaine Has No Clinical Impact on Fibromyalgia

Share this content:
Intravenous Lidocaine Has No Clinical Impact on Fibromyalgia
Intravenous Lidocaine Has No Clinical Impact on Fibromyalgia

HealthDay News -- Intravenous lidocaine has no meaningful impact on patients with fibromyalgia, according to a study published in the International Journal of Rheumatic Diseases.

Ana Laura Albertoni Giraldes, MD, from the Federal University of São Paulo in Brazil, and colleagues conducted a randomized trial involving patients with fibromyalgia. Participants were randomized to receive lidocaine in saline solution or saline solution once a week for 4 weeks. All patients received amitriptyline for 8 weeks. Patients underwent pain assessment, completed the fibromyalgia impact questionnaire, and had levels of interleukins (IL) 1, 6, and 8 measured before and after treatment.

The researchers found that the lidocaine group had lower pain intensity at week 2 of treatment, but not at other time points assessed during 8 weeks. Both groups experienced a reduction in pain intensity at 8 weeks after the start of treatment. There was no difference between the groups in use of acetaminophen and tramadol, or in plasma levels of IL-1, -6, and -8. There was no difference between the groups in clinical manifestations or side effects.

"The combination of 240 mg of intravenous lidocaine (once a week for 4 weeks) with 25 mg of amitriptyline for 8 weeks had no meaningful impact in fibromyalgia patients," the authors write.

Reference

Albertoni giraldes AL, Salomão R, Leal PD, Brunialti MK, Sakata RK. Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: A randomized double-blind study. Int J Rheum Dis. 2016; doi:10.1111/1756-185X.12904.

You must be a registered member of Neurology Advisor to post a comment.

Sign Up for Free e-newsletters

CME Focus